| Name | 4basebio |
|---|---|
| Epic | 4BB |
| Isin | GB00BMCLYF79 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 790.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £122.75 | Debt ratio | n/a |
| Shares in issue | 15.54 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -52.59 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.94 | 52-week high / low | 703.85p / 1,337.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | 4basebio |
|---|---|
| Address | 25 Norman Way, Over, Cambridge, United Kingdom, CB24 5QE |
| Telephone | +44 (0)1223 967943 |
| Website | http://www.4basebio.com/ |
| Director | Position |
|---|---|
| Dr Heikki Lanckriet | CEO |
| Mr David John Roth | CFO |
| Mr Michael Wasserman | Non-Executive Director |
| Mr Hansjörg Plaggemars | Non-Executive Director |
| Mr Alexander Link | Non-Executive Director |
| Dr. Manja Hermina Elisabeth Maria Boerman | Executive Chairman |
| Mr Alan Malus | Independent Non-Executive Director |
| Dr Amy Walker | Chief Operating Officer |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 3.48 | 2.67 | 2.12 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 7.84 | 6.9 | 5.79 |
| Inventory / work in progress | 0.37 | 0.33 | 0.13 |
| Trade and other receivables | 0.28 | 0.11 | 0.05 |
| Cash and equivalents | 34.6 | 3.07 | 4.35 |
| Other current assets and asset held for resale | 1.63 | 1.51 | 1.36 |
| Total of all assets | 44.73 | 11.92 | 11.69 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 3.27 | 2.28 | 1.52 |
| Long term liabilities | 15.08 | 10.14 | 3.05 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 18.35 | 12.41 | 4.57 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 26.38 | -0.49 | 7.12 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 13.77 | 11.13 | 11.13 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -38.72 | -26.39 | -18.73 |
| Share premium account | 37.25 | 0.71 | 0.71 |
| Total equity | 26.38 | -0.49 | 7.12 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -12.04 | -8.35 | -5.84 |
| Pre-tax profit | -12.65 | -8.35 | -5.93 |